Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Hot Spotlight
2 min read
Breakthrough in Parkinson's Treatment: Positive Phase 3 Trial Results for Cerevel's Tavapadon
28 April 2024
On April 18th, Cerevel reported positive results from its Phase 3 TEMPO-3 trial for tavapadon, a D1/D5 receptor partial agonist aimed at treating Parkinson's disease.
Latest Hotspot
3 min read
Alkermes has started the Vibrance-1 Phase 2 trial to assess ALKS 2680 for treating Narcolepsy Type 1
28 April 2024
Alkermes plc has launched the Vibrance-1 study, a phase 2 clinical trial aimed at assessing the safety and effectiveness of ALKS 2680 versus a placebo in individuals diagnosed with type 1 narcolepsy.
"What" Series
2 min read
What is Triple-Negative Breast Cancer?
28 April 2024
Triple-Negative Breast Cancer (TNBC) is a subtype of breast cancer that lacks estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER-2) on its cells.
Latest Hotspot
2 min read
Atom Bioscience begins enrolling U.S. participants in a worldwide Phase 2b/3 study of an experimental chronic gout therapy
28 April 2024
Atom Bioscience focused on innovative therapies for metabolic and inflammatory conditions, has initiated patient enrollment across the United States for a Phase 2b/3 study of ABP-671.
Pharma Frontiers
10 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - April 27
28 April 2024
April 27th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Latest Hotspot
3 min read
Endeavor BioMedicines Secures $132.5M in Oversubscribed Series C to Advance Medical Pipeline
28 April 2024
Endeavor BioMedicines has successfully secured $132.5 million in an oversubscribed Series C funding round to progress their groundbreaking medical pipeline.
"What" Series
2 min read
What clinical indicator is BCVA?
28 April 2024
BCVA stands for Best Corrected Visual Acuity, which is a key indicator commonly used in ophthalmic clinical trials to evaluate a patient's visual acuity.
Latest Hotspot
3 min read
Arrowhead Pharmaceuticals Initiates Phase 1/2a Trial of ARO-CFB for Kidney Diseases Linked to Complement System Dysfunctions
26 April 2024
Arrowhead Pharmaceuticals has started a Phase 1/2a trial for ARO-CFB aimed at treating kidney diseases caused by complement system dysfunctions.
Pharma Frontiers
9 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - April 26
26 April 2024
April 26th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Latest Hotspot
3 min read
FDA Approves Novartis's Lutathera® as First Specific Treatment for Young Patients with Gastroenteropancreatic Neuroendocrine Tumors
26 April 2024
The FDA has approved Novartis's radioligand treatment, Lutathera®, as the initial specific drug for young patients with neuroendocrine tumors of the gastroenteropancreatic area.
"What" Series
2 min read
What is the Therapeutic Index (TI)?
26 April 2024
The Therapeutic Index (TI) is an important parameter in assessing the safety of drugs. It is used to measure the relationship between the safety and effectiveness of a drug.
Latest Hotspot
3 min read
EU Commission Approves Expanded Use of Astellas' XTANDI™ for Early-Stage Recurrent Prostate Cancer
26 April 2024
European Commission approves Astellas' XTANDI™ (Enzalutamide) for expanded use in recurrent early-stage prostate cancer treatment.